During the past decade, Cincinnati Eye Institute conducted 49 clinical trials. In the 10-year time frame, 49 clinical trials started and 23 clinical trials were completed, i.e. on average, 46.9% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 19 clinical trials were completed. i.e. 76% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cincinnati Eye Institute" #1 sponsor was "Hoffmann-La Roche" with 12 trials, followed by "Genentech, Inc." with 6 trials sponsored, "Gyroscope Therapeutics Limited" with 4 trials sponsored, "Johnson & Johnson Surgical Vision, Inc." with 4 trials sponsored and "Applied Genetic Technologies Corp" with 4 trials sponsored. Other sponsors include 27 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cincinnati Eye Institute" #1 collaborator was "National Eye Institute (NEI)" with 4 trials as a collaborator, "Novartis Pharmaceuticals" with 4 trials as a collaborator, "Chugai Pharmaceutical" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator and "Abbott Medical Optics" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Cincinnati Eye Institute" are "Geographic Atrophy" (9 trials), "Macular Degeneration" (7 trials), "Cataract" (4 trials), "Dry Age-related Macular Degeneration" (4 trials) and "Diabetic Macular Edema" (3 trials). Many other conditions were trialed in "Cincinnati Eye Institute" in a lesser frequency.

Most popular intervention types in "Cincinnati Eye Institute" are "Drug" (40 trials), "Device" (12 trials), "Procedure" (9 trials), "Biological" (8 trials) and "Other" (7 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (7 trials), "Faricimab" (6 trials), "Placebo" (5 trials), "Aflibercept" (4 trials) and "Lampalizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Cincinnati Eye Institute" are 60 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Cincinnati Eye Institute". undefined are not yet recruiting, 6 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in Cincinnati Eye Institute, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Cincinnati Eye Institute, 6 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 7 trials that are defined as “Not Applicable".